Evidence map›Paper›PMID 35110300›Full record

Trial reportBMJ (Clinical research ed.)2022

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.

Mocrane Abbar, Christophe Demattei, Wissam El-Hage, Pierre-Michel Llorca, Ludovic Samalin, Pierre Demaricourt, Raphael Gaillard, Philippe Courtet, Guillaume Vaiva, Philip Gorwood and 2 more

3 registry-linked trialsAbstract readRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 78 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02299440 phase3completednot on this map

Evaluation of the Effects of Ketamine in the Acute Phase of Suicidal Ideation: a Multicenter Randomized Double-blind Trial

TypeinterventionalSponsorCentre Hospitalier Universitaire de NīmesRan2015 to 2019Enrolled156ConditionsSuicidal IdeationArmsBaseline evaluation, 1st perfusion of ketamine, 1st perfusion of saline, Follow-up between perfusions, 2nd perfusion of ketamine
NCT06957704 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

TypeinterventionalSponsorFederal University of São PauloRan2025 to 2028Enrolled60ConditionsDepressive Disorder, Suicidal IdeasArmsketamine, Midazolam
NCT07120477 phase4suspendednot on this mapstarted 2026, after this paper: background citation

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

TypeinterventionalSponsorUniversity of Sao PauloRan2026 to 2029Enrolled468ConditionsSuicide Prevention, Ketamine, Crisis Response PlanArmsIntravenous Esketamine, Crisis Response Planning intervention (structures safety planning)
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Inflammation and treatment strategies for suicidal behavior.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mocrane AbbarDepartment of Psychiatry, Academic Hospital (CHU) Nîmes, University of Montpellier, Nîmes, France.
Christophe DematteiDepartment of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU Nîmes, University of Montpellier, Nîmes, France.
Wissam El-HageCHRU Tours, Research Unit (UMR) 1253, iBrain, University of Tours, National Institute for Health and Medical Research (INSERM), Tours, France.
Pierre-Michel LlorcaDepartment of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, UMR 6602, Institute Pascal, Clermont-Ferrand, France.
Ludovic SamalinDepartment of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, UMR 6602, Institute Pascal, Clermont-Ferrand, France.
Pierre DemaricourtSchool of Medicine, University of Paris and Sainte-Anne Hospital, Paris, France.
Raphael GaillardSchool of Medicine, University of Paris and Sainte-Anne Hospital, Paris, France.
Philippe CourtetINSERM, Centre for Epidemiological and Clinical Research in Psychiatry (PSNREC), University of Montpellier, CHU Montpellier, Montpellier, France.
Guillaume VaivaDepartment of Psychiatry, CHU Lille, Lille, France.
Philip GorwoodSchool of Medicine, University of Paris and Sainte-Anne Hospital, Paris, France.
Pascale FabbroDepartment of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU Nîmes, University of Montpellier, Nîmes, France.
Fabrice JollantDepartment of Psychiatry, Academic Hospital (CHU) Nîmes, University of Montpellier, Nîmes, France jollantf@gmail.com.ORCID 0000-0001-5809-4503

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group.

designProspective, double blind, superiority, randomised placebo controlled trial.

settingSeven French teaching hospitals between 13 April 2015 and 12 March 2019. ELIGIBILITY CRITERIA FOR

participantsAged 18 or older with current suicidal ideation, admitted to hospital voluntarily. Exclusion criteria included a history of schizophrenia or other psychotic disorders, substance dependence, and contraindications for ketamine.

participants156 participants were recruited and randomised to placebo (n=83) or ketamine (n=73), stratified by centre and diagnosis: bipolar, depressive, or other disorders.

interventionTwo 40 minute intravenous infusions of ketamine (0.5 mg/kg) or placebo (saline) were administered at baseline and 24 hours, in addition to usual treatment.

main outcome measuresThe primary outcome was the rate of patients in full suicidal remission at day 3, according to the scale for suicidal ideation total score ≤3. Analyses were conducted on an intention-to-treat basis.

resultsMore participants receiving ketamine reached full remission of suicidal ideas at day 3 than those receiving placebo: 46 (63.0%) of 83 participants in the ketamine arm and 25 (31.6%) of 73 in the placebo arm (odds ratio 3.7 (95% confidence interval 1.9 to 7.3), P<0.001). This effect differed according to the diagnosis (treatment: P<0.001; interaction: P=0.02): bipolar (odds ratio 14.1 (95% confidence interval 3.0 to 92.2), P<0.001), depressive (1.3 (0.3 to 5.2), P=0.6), or other disorders (3.7 (0.9 to 17.3, P=0.07)). Side effects were limited. No manic or psychotic symptom was seen. Moreover, a mediating effect of mental pain was found. At week 6, remission in the ketamine arm remained high, although non-significantly versus placebo (69.5%

conclusionsThe findings indicate that ketamine is rapid, safe in the short term, and has persistent benefits for acute care in suicidal patients. Comorbid mental disorders appear to be important moderators. An analgesic effect on mental pain might explain the anti-suicidal effects of ketamine.

trial registrationClinicalTrials.gov NCT02299440.

Indexed as

Patient AcuitySuicidal IdeationAdolescentAdultAgedAnalgesicsDepressionDouble-Blind MethodFemaleHumansKetamineMaleMiddle AgedProspective StudiesRemission InductionYoung AdultAnalgesicsKetamine

Identifiers

PMID35110300
PMCPMC8808464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.